Treatment heterogeneity in asthma: Genetics of response to leukotriene modifiers

Molecular Diagnosis and Therapy

Volumn 11, Issue 2, 2007, Pages 97-104

  Lima, John J ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; BRONCHOCONSTRICTING AGENT; CORTICOSTEROID DERIVATIVE; CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; THEOPHYLLINE; UNCLASSIFIED DRUG; VERLUKAST; ZARFIRLUKAST; ZILEUTON;

AREA UNDER THE CURVE; ASTHMA; BILIARY EXCRETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; LIVER CLEARANCE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 34147189140     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256228     Document Type: Review

References (70)

1. Sly RM. Decreases in Hispanic and non-Hispanic asthma mortality. Ann Allergy Asthma Immunol 2006; 96: 76-9
2. American Lung Association. Trends in asthma morbidity and mortality [online]. Available from URL: http://www.lungusa.org/atf/cf/%7B7A8D42C2-FC-CA- 4604-8ADE-7F5D5E762256%7D/ASTHMA1.PDF [Accessed 2007 Mar 2]
3. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168-70
4. Becker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med Hypotheses 2004; 62: 309-17
5. Lima JJ, Wang J. Respiratory diseases. In: American College of Clinical Pharmacy, editor. Pharmacogenomics: applications to patient care. Kansas City (MO): ACCP, 2004: 571-611
6. Silverman ES, Liggett SB, Gelfand EW, et al. The pharmacogenetics of asthma: a candidate gene approach. Pharmacogenetics 2001; 1: 27-37
7. Pignatti PF. Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res 2004; 49: 343-9
8. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep 2005; 5: 101-8
9. Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics 2006; 6: 311-26
10. O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 2006; 368: 794-803
11. Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 145-55
12. Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 2006; 14: 10-6
13. Capra V, Thompson MD, Sala A, et al. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev. Epub 2006 Aug 7
14. Ramires R, Caiaffa MF, Tursi A, et al. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004; 324: 815-21
15. National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics 2002: NAEPP2002. J Allergy Clin Immunol 2002; 110: S142-219
16. O'Byrne P, Bateman ED, Busse W, et al. Pocket guide for asthma management and prevention [NIH publication no. 02-3659]. Bethesda (MD): National Institutes of Health, 2005
17. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150: 618-23
18. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 1996; 98: 859-71
19. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1997; 126: 177-83
20. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213-20
21. DuBuske LM, Grossman J, Dube LM, et al. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am J Manag Care 1997; 3: 633-40
22. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130: 487-95
23. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110: 847-54
24. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-42
25. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-51
26. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157: 1187-94
27. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-8
28. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002; 324: 1545-8
29. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus antileukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006; (4): CD003137
30. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175: 235-42
31. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173: 379-85
32. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49
33. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130-7
34. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl. 2: S28-31
35. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12: 565-70
36. Whelan GJ, Blake K, Kissoon N, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol 2003; 36: 413-20
37. Currie GP, Lima JJ, Sylvester JE, et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 2003; 56: 422-6
38. Currie GP, Lee DK. Uncertain biological relevance of polymorphisms of leukotriene C4 synthase in asthma [letter]. J Allergy Clin Immunol 2005; 115: 205
39. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74
40. Wong SL, Awni WN, Cavanaugh JH, et al. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet 1995; 29 Suppl. 2: 9-21
41. Lu P, Schrag ML, Slaughter DE, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352-60
42. Machinist JM, Kukulka MJ, Bopp BA. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet 1995; 29 Suppl. 2: 34-41
43. Awni WM, Wong S, Chu SY, et al. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. J Clin Pharmacol 1997; 37: 395-404
44. Frye R. Pharmacogenetics of oxidative drug metabolism and its clinical applications. In: Thomas SJ, editor. Pharmacogenomics. Kansas City (MO): American College of Clinical Pharmacy, 2004: 273-307
45. Bernstein PR. Chemistry and structure: activity relationships of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998; 157: S220-5
46. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000; 59: 891-928
47. Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001; 61: 285-315
48. Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 2002; 41: 105-14
49. Keam SJ, Lyseng-Williamson KA, Goa KL. Pranlukast: a review of its use in the management of asthma. Drugs 2003; 63: 991-1019
50. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2000; 46: 3-26
51. Kim RB. Transporters and drug discovery: why, when, and how. Mol Pharm 2006; 3: 26-32
52. Sai Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab Pharmacokinet 2005; 20: 91-9
53. Kroetz D, Nyguyen T. Drug transporter pharmacogentics. In: Thomas J, editor. Pharmacogenomics. Kansas City (MO): American College of Clinical Pharmacy, 2004: 309-36
54. Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 1998; 38: 431-60
55. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231-59
56. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469-97
57. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5: 273-82
58. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-65
59. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4-33
60. Chiba M, Xu X, Nishime JA, et al. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997; 25: 1022-31
61. Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996; 13: 445-8
62. Zhao JJ, Rogers JD, Holland SD, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997; 18: 769-77
63. Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. Pharm Res 2005; 22: 532-40
64. Balani SK, Xu X, Pratha V, et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997; 25: 1282-7
65. 4 receptor antagonist, MK-0476. Int J Pharm 1996; 14: 59-70
66. Letschert K, Faulstich H, Keller D, et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006; 91: 140-9
67. Kobayashi D, Nozawa T, Imai K, et al. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306: 703-8
68. Leier I, Jedlitschky G, Buchholz U, et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994; 269: 27807-10
69. Leier I, Jedlitschky G, Buchholz U, et al. Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 1994; 220: 599-606
70. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005; 4: 664-72